Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,257,310
  • Shares Outstanding, K 49,535
  • Annual Sales, $ 336,890 K
  • Annual Income, $ -87,940 K
  • EBIT $ -76 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.95
  • Price/Sales 6.51
  • Price/Cash Flow N/A
  • Price/Book 9.59

Options Overview Details

View History
  • Implied Volatility 53.21% ( -2.44%)
  • Historical Volatility 51.78%
  • IV Percentile 15%
  • IV Rank 34.23%
  • IV High 93.35% on 05/31/24
  • IV Low 32.33% on 05/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 27
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 2,866
  • Open Int (30-Day) 2,690

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.33
  • Number of Estimates 4
  • High Estimate -0.29
  • Low Estimate -0.41
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +36.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.83 +20.46%
on 04/16/25
47.43 -3.92%
on 05/08/25
+5.99 (+15.13%)
since 04/11/25
3-Month
36.88 +23.56%
on 04/09/25
54.23 -15.98%
on 02/21/25
-5.15 (-10.15%)
since 02/12/25
52-Week
23.83 +91.23%
on 05/31/24
54.23 -15.98%
on 02/21/25
+20.81 (+84.05%)
since 05/10/24

Most Recent Stories

More News
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

MIRM : 45.57 (+2.94%)
VTI : 287.27 (+3.35%)
IWM : 207.87 (+3.52%)
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

We expect investors to focus on updates related to Sol-Gel Technologies, Ltd.’s SLGL ability to regain compliance with the recent Nasdaq requirement and other pipeline development activities when it...

MIRM : 45.57 (+2.94%)
SLGL : 7.50 (-4.46%)
PCRX : 25.09 (-0.12%)
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

Castle Biosciences, Inc. CSTL is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is...

MIRM : 45.57 (+2.94%)
CSTL : 17.04 (+1.52%)
PCRX : 25.09 (-0.12%)
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?

We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other pipeline updates when it reports fourth-quarter 2024 results.See the Zacks Earnings...

VKTX : 28.30 (+2.72%)
MIRM : 45.57 (+2.94%)
ADMA : 20.45 (+2.35%)
PCRX : 25.09 (-0.12%)
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024,...

CTMX : 2.13 (+129.43%)
MIRM : 45.57 (+2.94%)
VYGR : 3.35 (+5.68%)
CSTL : 17.04 (+1.52%)
Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally...

IMCR : 29.54 (+4.01%)
MIRM : 45.57 (+2.94%)
CSTL : 17.04 (+1.52%)
SPRO : 0.6100 (-1.61%)
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

Mirum Pharmaceuticals, Inc. MIRM incurred a loss of 30 cents per share in third-quarter 2024, much narrower than the Zacks Consensus Estimate of a loss of 45 cents. The company had reported a loss of 57...

IMCR : 29.54 (+4.01%)
MIRM : 45.57 (+2.94%)
CSTL : 17.04 (+1.52%)
ANIP : 62.30 (-6.03%)
United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023

Stocks that traded heavily or had substantial price changes on Monday: United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall

MIRM : 45.57 (+2.94%)
NIO : 4.20 (+5.79%)
ILMN : 81.57 (+7.67%)
VLO : 130.49 (+6.15%)
ADBE : 395.94 (+3.30%)
DOOR : 132.84 (+0.05%)
Why Shares of Travere Therapeutics Are Slumping Thursday

A mixed trial could hurt a kidney drug's chances of full approval.

TVTX : 21.54 (+7.59%)
MIRM : 45.57 (+2.94%)
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.

MIRM : 45.57 (+2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 47.70
2nd Resistance Point 46.96
1st Resistance Point 46.27
Last Price 45.57
1st Support Level 44.84
2nd Support Level 44.10
3rd Support Level 43.41

See More

52-Week High 54.23
Last Price 45.57
Fibonacci 61.8% 42.62
Fibonacci 50% 39.03
Fibonacci 38.2% 35.44
52-Week Low 23.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar